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1.1 Introduction. 
1.1.0 The concept of IIM
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of chronic, 
systemic disorders; defined by progressive loss of striated muscle tissue and with an unknown 
aetiology[1]. These disorders are on the basis of unique clinical, histopathological, 
immunological and demographic features differentiated into three distinct and major subsets; 
polymyositis (PM), dermatomyositis (DM) and sporadic inclusion body myositis (sIBM).[2, 
3]. This introduction will first describe PM/DM separately and then make a separate part for 
sIBM
1.1.1 History of PM/DM 
Approximately 125 years ago, Unverricht recorded the first description in the medical 
literature of PM. This was followed a year later by Jacoby`s article in the United States 
literature. The earliest well documented cases were by Eaton in 1954, followed by an article 
by Walton in 1956, then two by Barwick and Walton in 1960 and 1963. In the 70s Rose and 
Walton and finally Pearson published clinical patterns of PM/DM.[3-7] What gradually 
emerged from these studies was a clear clinical picture of PM and DM. In the recent years 
new information about pathology and serum auto-antibodies has increased the knowledge and 
awareness of these systemic autoimmune disorders. 
1.1.2 Clinical features of PM and DM: 
DM and PM are characterized clinically by progressive symmetrical proximal muscle 
weakness of the shoulders, neck and hips.[2] The muscle involvement can have an acute,  
sub-acute or a more insidious onset, but the patients typically begin to notice fatigue of their 
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muscles or weakness when climbing stairs, walking, rising from a sitting position, combing 
their hair, or reaching for items in cabinets that are above their shoulders. Muscle tenderness 
(myalgia) and stiffness may occur.[2, 8] The typical rash of DM patients include; Heliotrope 
rash, Gottron`s papules or sign, V and Shawls sign.  The rashes are purple-to-erythematous, 
scaly, and may demonstrate both hyperpigmentation and hypopigmentation, as well as 
telangiectasia and epidermal atrophy in son-exposed areas-typically described as V-sign at the 
front of chest and Shawl seen on the neck after sun-exposure (poikilodermatous).[9, 10] 
Heliotrope rash typically affects the eyelids and are described as purple and edematous, while 
the Gottron`s papules are typically described as erythematous to violaceous papules over the 
extensor surfaces of joints, which are sometimes scaly. This manifestation may occur over the 
finger joints, elbows, knees, malleoli and toes. The Gottrons sign is erythematous to 
violaceous macules over the extensor surfaces of joints, which are not palpable. 
There are however some DM patients with rash, which have little or no muscle disease. These 
subgroups of DM are called amyopathic or hypomyopathic DM or Clinically Amyopathic 
Dermatomyositis (CADM). In addition to the manifestations of skin and muscle a significant 
number of patients exhibit oesophageal dysmotility and dysphagia, affection of joints with the 
symptoms of arthralgia and arthritis, Raynaud, Sicca phenomenon, fever and flu-like 
symptoms and to a lesser extent calcinosis cutis and mechanic’s hands.[1] Mechanic`s hands 
are scaly, fissured hyperkeratotic lesions on the lateral and palmar surfaces hands. These 
fissure-like cracks in the palms of the hands are in some cases black and resemble the hands 
of a hard-working manual labourer, hence the name. This feature is typically seen in patients 
with anti-synthetase syndrome (ASS) (see later).  
Both PM and DM are regarded as systemic diseases with frequent manifestations in the 
gastrointestinal tract, joints, pulmonary and cardiovascular systems [1, 9, 11]. Both the muscle 
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and skin affection may lead to severe disability and morbidity, but the major clinical problem 
is acute and chronic lung involvement and secondary pulmonary hypertension (PH). The 
prevalence of pulmonary involvement and ILD has been reported to vary between 20% and 
80% in ethnically diverse populations and is considered to be a common cause of morbidity in 
these patients.[12-20]. Cardiac complications include heart failure, arrhythmias, ventricular 
dysfunction[21]. Oesophageal involvement is considered to be frequent in PM/DM occurring 
in 20 to 84% of patients and encompasses asymptomatic patients to life-threatening 
complications (aspiration pneumonia, need for total enteral feeding due to aphagia) [22, 23].
1.1.3 Classification of PM/DM 
In 1975, Bohan and Peter published a classic article that suggested a set of criteria to aid in the 
diagnosis and classification of DM and PM [24-26]. The Peter & Bohan diagnostic criteria 
from 1975 are still regarded as “ the  gold standard” when classifying PM and DM cases for 
research purposes (Table 1).[27] The classical Peter and Bohan criteria include key clinical 
features (muscle weakness and DM rash) and laboratory parameters (serum level of muscle 
enzymes, electromyography (EMG) and muscle histology), but not Myositis Associated 
Autoantibodies (MAA) or magnetic resonance imaging (MRI) of muscle tissue (Table 1). 
Revised classification criteria, building  on the Peter & Bohan criteria, with inclusion of MAA 
and MRI were proposed by Targoff et al in 1997 (Table 2).[28]
Several investigators have proposed alternative PM/DM classification criteria (Medsger 1970, 
DeVere 1975,Dalakas 1991 and 2003, Tanimoto 1995, Mastalgia 2002, Hoogendijk 2004 and 
Christopher-Stine 2010.[2, 29-35]. Most criteria have been found to have some limitations. 
The earliest criteria lack clear instructions how to rule out other forms of myopathy, and 
sIBM not included as a separate entity. In addition, the earliest criteria do not specify and 
characterize the rash in DM. The sensitivity and specificity for many confounding 
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dermatological and neuromuscular disorders have in addition not been evaluated. [36, 37] The 
limitations of the more recent criteria are that they are based on case-series from single centre, 
based on clinical observations, rather than data-analysis. And none have been tested for 
sensitivity and specificity by appropriate powered studies against all the appropriate disease 
confounders.[36, 37] 
Table 1 Peter and Bohan Criteria 
1 progressive proximal symmetrical weakness 
2 Elevated serum enzymes, not only CK, but also aldolase, AST, ALT and LD. 
3 Abnormal electromyogram with myopathic motor unit potentials, fibrillations, sharp 
waves, increased insertional irritability an abnormal electromyogram 
4  Muscle biopsy evidence of necrosis of myofibers, phagocytosis, regeneration with 
basophils, large vesicular sarcolemma nuclei, and prominent nucleoli, atrophy in a 
perifascicular distribution, variation in fiber size and an inflammatory exudate, often 
perivascular.
5 Typical skin rash of DM; including Heliotrope rash, Gottrons papules or sign. 
x 3 positive criteria are  classified as probable IIM 
x 4 positive criteria are classified as definite IIM 
x Additional positive typical skin rash of DM (No 5), classifies the patient as DM. 
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Table 2 Targoff diagnostic criteria for PM/DM. Any three items equals probable 
PM/DM and any four criteria equals definite diagnosis.[28]  
x Including Anti-synthetase (anti-Jo 1, anti-PL 12, anti-PL 7) and anti-Mi2 and anti-
SRP autoantibodies. 
More recently, larger scale consensus efforts have been undertaken by the International 
Myositis Classification Criteria Project (IMCCP) with objectives to develop and validate new 
classification criteria for IIM. The methods utilized by IMCCP are the usage of candidate 
variables selected from published criteria. These have been assessed on international 
multicentre recruited IIM patients, 973 in total. Two probability score models have been 
Items in Targoff   
Symmetric proximal muscle weakness 1 
Elevated serum enzymes, not only Creatine Kinase (CK), but also 
aldolase, AST, ALT and LD.
2
Abnormal electromyogram with myopathic motor unit potentials, 
fibrillations, sharp waves, increased insertional irritability 
3
 Muscle biopsy evidence of necrosis of myofibers, phagocytosis, 
regeneration with basophils, large vesicular sarcolemma nuclei, and 
prominent nucleoli, atrophy in a perifascicular distribution, variation 
in fiber size and an inflammatory exudate, often perivascular. 
4
Typical skin rash of DM; including Heliotrope rash, Gottrons papules 
or sign. 
5
Any one of the Myositis Associated autoantibody* 6 
Pathological MRI findings consistent with inflammation May substitute 
criterion 1 or 2
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developed; Model 1: clinical variables on muscle, skin and laboratory measures. Model 2 
which additionally comprised muscle biopsy variables. These two models were found 
superior to existing criteria, and  external validating is in progress.[37] 
Interestingly, preliminary data from IMCCP, presented at the EULAR-meeting in 2014 
indicated that the Targoff criteria show the best sensitivity and specificity of established 
criteria. [37].
1.1.4 Pathology of PM/DM 
Biopsies from weakened muscles in PM or DM typically show myositis with inflammatory 
cell infiltration of muscle tissue accompanied by degeneration and regeneration of muscle 
fibres. Accumulated evidence from immune-histochemical studies suggests wide 
heterogeneity of the infiltrates. In patients with clinical DM one often identifies peri-vascular 
accumulations of CD4+ T cells, B cells and plasmacytoid dendritic cells. In contrast, the 
infiltrates in PM and, to some degree, also in sIBM mainly consists of activated CD8+ T cells. 
[38]
1.1.5 Aetiology and pathogenesis of PM/DM: 
By definition, the causes of PM/DM remain unknown: However, data from similar 
autoimmune disease support the hypothesis that these conditions result from chronic immune 
activation after exposure to environmental risk factors in individuals with a predisposing 
background.[39] Genetic associations are more linked to  clinical phenotypes  and 
autoantibodies than with myositis patients as a whole. Genetic factors for myositis also vary 
by age of onset, ethnicity, and environmental exposure group.[40] The genetic risk factors 
include polymorphism of many genes that regulate responses to environmental agents, 
particularly human leukocyte antigen (HLA), and cytokine and immunoglobulin genes.[41-
16

43]. Current findings suggest that human leukocyte antigen (HLA) genes on chromosome 6, 
particularly HLA DRB1*0301 and the linked allele DQA1*0501, have the strongest 
associations with all clinical forms of IIM in white patients.[44] Familial autoimmunity in 
pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors 
for many autoimmune diseases.[45] 
It is speculated that the autoantigens need certain ‘micro-environments for example, lung, 
skin, muscle or tumour tissue. And that these micro-environments need specific triggers such 
as UV light, infection or misdirected anti-tumour response which in turn lead to the over-
expression of proteins (Jo-1, Mi-2, TIF1 and others) by apoptotic cells. It is believed that 
granzyme B generated fragments become immunogenic, and that corresponding autoantigens 
develop chemo-attractant properties leading to tissue injury and autoimmune responses. [46] 
1.1.6 Myositis Specific Autoantibodies and clinical phenotypes: 
Autoantibodies are common in PM and DM, and more than ten different, mutually exclusive 
myositis specific antibodies (MSA) have been described.[46] Interestingly, the MSA are 
associated with distinct clinical syndromes that often cross the classical distinction between 
PM and DM.[40, 47, 48]The most common of these autantibody-associated IIM syndromes 
are described below. 
Anti-synthetase syndrome: The main MSA are the Anti-synthetase autoantibodies (ASS) 
which forms the largest subgroup in IIM patients. Anti Jo-1 is the most frequent one and one 
of the first described (Table 3). [49, 50] The ASS are mutually exclusive. ASS has been well 
described, and classic clinical features include myositis, interstitial lung disease (ILD), 
Raynaud’s, mechanic’s hands, Gottron’s lesions, non-erosive inflammatory arthritis and fever. 
ILD is a major manifestation and the most commonly encountered radiological and 
histological patterns are Non-Specific Interstitial Pneumonia (NSIP) and Cryptogenic 
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Organizing Pneumonia (COP). This group of patients may have Usual Interstitial Pneumonia 
(UIP), the radiological and histological pattern synonymous with Idiopathic Pulmonary 
Fibrosis (IPF). ILD is reported in 50–95 % of ASS patients, but it is clear that even within the 
ASS spectrum, anti-Jo1 differs from non-anti-Jo1 ASS patients.[51-58] The non-anti-Jo1 ASS 
clinical phenotype may be present with lung disease first, and patients may never develop 
myositis, have subclinical myopathy or milder muscle disease.  
Table.3. Types of Antisynthetase syndrome autoantibodies 
Name Antigen 
Anti-Jo 1 Histidyl-tRNA synthetase 
Anti-PL12 Alanyl tRNA synthetase 
Anti-PL7 Threonyl tRNA synthetase 
Anti-OJ Isoleucyl tRNA synthetase 
Anti-EJ Glycyl tRNA synthetase 
Anti-KS Asparaginyl tRNA synthetase 
Anti-Zo Fenylalanin tRNA synthetase 
Anti-Ha Tyrosyl tRNA synthetase 
Necrotizing Myopathy Syndromes; Autoimmune necrotizing myopathy (ANM) is a relatively 
newly recognized subgroup of IIM  that are defined by common clinical and histopathological 
features (Table 4) [46]. Patients present with sub-acute proximal weakness with high CK 
levels. On muscle biopsy, characteristic features include myofibre necrosis, minimal 
endomysial and perivascular inflammatory infiltrate, and in some cases focal endomysial 
fibrosis [59]. Despite little or no muscle inflammation, ANM usually responds to immune 
modulatory therapy highlighting that this is an immune-mediated phenotype associated with 
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two specific autoantibodies (Table 4).Other MSA :Recently new MSA have been discovered; 
anti-Transcription intermediary factor -1g (anti-TIF-1g), anti-nuclear matrix protein 2 (anti-
NXP2), anti-melanoma differentiating antigen 5 (anti-MDA5), anti-small ubiquitin-like 
modifier enzyme heterodimer 1/2 (anti-SAE1/2) and anti- cytosolic 5-nucleotidase 1A ( anti-
Mup44).(Table 4). 
Table 4 Other Myositis Associated Autoantibodies (MSA) 
 Clinical features Reference 
Anti-SRP AMN with high CK, serious myopathy, dysphagia, 
cardiac muscle involvement and arthritis. 
[51, 60]
Anti-HMG-
coA
AMN associated with prior statin exposure, significant 
weakness and high CK levels. 
[61, 62]
Anti-MDA5 . Amyopathic dermatomyositis (ADM), severe, acute 
ILD.
[63, 64] 
Anti-Mi2  Classical DM,  low frequency of cancer-associated 
myositis (CAM),  
[65]
Anti-TIF-1g DM and Cancer associated myositis (CAM) in adults. 
systemic features and severe skin disease. 
 [66, 67] 
Anti-NXP2 JDM, lower frequency adult patients [68-70]
Anti-SAE  CADM with classic skin disease first. Later go onto 
develop myositis with a higher frequency of systemic 
involvement; dysphagia and gastrointestinal disease.
[71, 72] 
Anti-MUP44 Associated with sIBM [73, 74] 
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1.1.7 Epidemiology PM/DM: 
The epidemiology of PM/DM is largely unknown and only a few epidemiological studies 
have been published.  Research into these disorders has been limited by the rarity of the 
disease, a somewhat insidious onset, difficulties with classification and diagnostic methods, a 
heterogeneous study population and selection bias [75, 76]. In general, DM seems the most 
common and PM the least common. DM affects both children and adults, whereas PM 
generally occurs after the second decade of life. As to gender, when considering the DM–PM 
as a whole, the female/male ratio is about 2:1. The reported incidence ranges between two and 
eight new cases per million of inhabitants per year [39, 47, 76-78] Few studies have been 
undertaken in Europe. Annual incidence of 7.6 cases/million was estimated in an country-
cased Swedish study[79]. 
Prevalence data for PM and DM vary from  5/100 000 between 21.5/100 000 depending on 
methods used for obtaining data, highest estimations done by calculated by medical 
administrative data in USA and Canada. [39, 80-82] To our knowledge, there is only one 
population based study on DM, with 29 cases defined solely by clinical features,[83]) and 
some few retrospective studies based on chart reviewing.[4, 31, 76, 79, 84-88] The largest of 
these chart review studies, performed in the Allegheny County in Pennsylvania from 1963-82, 
used predefined clinical criteria for case assignment and identified 177 PM/DM cases. 
Interestingly, the study reported that the PM/DM incidence tripled during the study period. 
[76]
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1.1.8. Morbidity in PM/DM 
Although PM and DM are regarded as treatable disorders, prognosis is not well known, as in 
the literature long-term outcome and prognostic factors vary widely- favourable outcome is 
reported to be between 18 to 90% depending on study.[27, 32, 47, 89, 90] To date, although 
overall prognosis appears to be better, PM and DM are still considered to be associated with 
increased morbidity, primarily related to severe muscle weakness and visceral 
involvement.[91] Recent series underline that only 20% to 40% of treated patients will 
achieve PM/DM remission, whereas 60% to 80% will experience a polycyclic or chronic, 
continuous course of the disease. PM/DM further continues to have a great impact on life in 
medium- and long-term follow-up, as up to 80% of treated patients are still disabled (using 
Health Assessment Questionnaire scores).[89, 91] Predictive factors for a poor prognosis in 
PM/DM patients are older age, delay in cortisone treatment, involvement of lung and cardiac 
systems, difficulty swallowing, cancer, and serum myositis-associated antibodies (anti-Ro52 
and anti-Jo1 antibodies, anti-SRP, Anti-TIF-1g and anti-MDA5 antibodies).[12, 89, 91] Series
by Marie et al. underlies the high frequency of ILD in PM/DM patients, resulting in increased 
morbidity and mortality rates. It also indicates that PM/DM patients should routinely be 
screened for ILD. Because of the poor outcome of ILD, it may require more aggressive 
therapy.[15]
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1.1.9 Survival in PM/DM 
Studies from the 1970s indicated increased mortality in PM/DM. [4, 92-95] Later work have 
confirmed this, but shown large variation in mortality rates, probably due to differences in 
patient selection, classification and loss to follow-up. [91] Peter and Bohan criteria have been 
applied in eight studies on mortality (table 5), [89, 90, 96-101] but only one of these eight 
studies was performed on an unselected population based cohort. [98] This study, which is the 
largest mortality study to date, performed hospital discharge searches for PM/DM cases by 
the 7th International Classification of Disease version 7 (ICD-7) codes and subsequent case 
assignment by chart review to identify 248 PM/DM patients diagnosed in Finland from 1969-
1985, followed until death or 1995. Mortality rates in this study were assessed by life-tables 
[98], and not by matched population controls [89]. Available data indicate that major causes 
of death in PM/DM are cancer, infections and cardiopulmonary complications. [91, 98] 
Prognostic factors vary between studies, but older age, cardiopulmonary disease, cancer and 
the presence of MAA have all been associated with poor outcome.
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Table 5 Mortality studies in patients with PM/DM 
Study Year and 
location 
Patients 
with
PM/DM,
Survival
at 5 y,%
Mortality,
%
Comments and criteria 
Medsger
et al.[93]
1971
US 
124  65 36.4% 1947-1968, ICDA codes and 
chart review. Multicentre 
Life-table
Benbassat
et al. 
[102]
1985
Israel 
92 52 32.6 1956-1976, chart review, Peter 
and Bohan (P&B)
Multi-centre.  
Hochberg
et al. 
[103]
1983
US 
1986
deaths
attributed
to
PM/DM
codes
n.d Calculated 
Relative 
risk for 
patients 
according 
to gender, 
age and 
race. 
1968 -1978. ICD-8 codes, no 
chart review. Nation-wide 
Death records from US 
Marie et 
al. [90] 
2001
France
77  77  22.1 1983-1998, chart review, no 
codes, (P&B), single centre.   
Sultan et 
al. [96] 
2002
UK
46  95  13 1978-1999, chart review, P&B 
criteria. single centre
Danko et 
al. [99] 
2004
Hungary
162 92 12.3 1976-1997, chart review, P& 
B. Single centre 
Airio et 
al. [98] 
2006
Finland
248 75 (PM) 
63 (DM) 
60.1 1969-1985, ICD-7 code, chart 
review. P & B. 
Nation-wide
Bronner
et al. [89] 
2006
Netherlands
165 n.d 21 1977-1998, chart review, 
P&B. Multicentre. 
Torres et 
al. [101] 
2006, Spain 107 80 27.5 25 year follow-up, chart 
review, P&B. Single centre. 
Yamasaki 
et al. 
[100]
2011, Japan 197  75  26.9 1984-2009. P&B, Sondheim’s 
for AMD. Single centre 
Yu et al. 
[104]
2011.
China
192  76 28.6 1999-2008, chart review. 
Single centre  
Schiopu
et al. [97]
2012, US 160  77 16.9 1997-2003, ICD-9 codes, chart 
review. P & B. Single centre
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1.1.10 Cancer risk DM/PM  
The first report suggesting an association between malignancy and DM was published in 
1916.[105] Since then, a large number of case series and case reports were described in the 
literature. However, the first case-control study confirming the association of DM/PM with 
malignancy was published years later in 1985.[106] Subsequent population-based 
retrospective cohort studies have consistently confirmed an increased risk of malignancy in 
the setting of DM and PM and recently in sIBM. Overall, these studies observed a 2-to 4 fold 
increased cancer risk in PM/DM, with highest incidence rates in the DM subset and in males 
older than 50 years.[105, 107-112] (Table 6), Cancer diagnosis can precede, parallel, or 
follow DM/PM diagnosis. The largest cancer study in PM/DM to date was a pooled analysis 
of data from Sweden, Denmark, and Finland.[105, 111, 112]  The study included 618 DM and 
914 PM patients identified by ICD-7 or ICD-8 hospital discharge diagnoses, but less than 1/3 
of these cases had their PM/DM diagnosis verified by chart review [109]. Standardized 
Incidence Rates (SIR) were estimated using National cancer registry data as reference and 
found to be 3.0 in DM and modestly increased, at 1.3 in PM.[109]. A recent retrospective 
study on biopsy-proven IIM cases from Victoria, Australia reported increased cancer risk 
across all IIM subsets, including sIBM. [111] Cancer subtype analyses indicated that the most 
common PM/DM associated malignancies were of ovarian, lung, gastrointestinal, breast or 
haematological origin.[105, 109-112]  
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Table 6 Overview over main cancer-studies in IIM: 
Study, year 
and location 
No
patients 
Cancer Case Finding  Comments 
Hill [113],
2001
Sweden,
Finland and 
Denmark 
618 DM
914 PM
SIR*
DM 3.0. 
PM
ICD-7/8 hospital 
discharge diagnoses, 
coupled to life table 
cancer registry
< 1/3 chart reviewed 
and classified by P&B 
Sigurgeirsson,
[112],
1992
Sweden
788
PM/DM
Relative 
risk  
DM 2.4, 
PM 1.8 
ICD-7/8 hospital 
discharge diagnoses. 
Coupled to life table 
cancer registry
1/10 chart reviewed and 
classified by P&B 
Chow [114],
1995
Denmark 
539 SIR  
DM 3.8 
PM 1.7 
ICD-8 hospital 
discharge diagnoses.. 
Coupled to life table 
Cancer registry
No chart reviews were 
performed to verify 
diagnosis
Airio[115]
1995
Finland
171 PM 
71 DM 
SIR
DM 6.5, 
PM  1.0
ICD-7/8 hospital 
discharge diagnoses. 
Coupled to life table 
cancer registry
All cases chart 
reviewed and classified 
by P & B 
Buchbinder,
R[111]
2001
Australia
103 IIM 
patients 
SIR
DM 6.0, 
PM 2.0 
sIBM 2.4 
Biopsy-proven IIM. 
Coupled to life table 
cancer registry 
All cases chart 
reviewed, classification 
criteria utilized not 
given.
Stockton[116]
2001
Scotland
286 DM 
419 PM 
SIR
DM, 7.7 
PM 2.1 
ICD-9 hospital 
discharge codes, 
coupled to life table 
cancer Registry 
No chart review 
performed to verify 
diagnosis
Limaye V et 
al[107]
2013
Australia
373 SIR  
DM 2.2,
PM 1.3 
sIBM 1.4 
Biopsy-proven IIM,
coupled to life table 
cancer Registry 
Chart review 
performed, 80%  met P 
& B
25

1.1.11 Treatment PM/DM 
Before the discovery of corticosteroids, the prognosis and outcome of IIM was poor and 
associated with high mortality and major disability. Due to the limited number of controlled 
trials utilizing validated outcome measures and the rarity and the heterogeneity of IIM, the 
treatment of IIM is complex and challenging.[117] Most treatment regimens are based on 
case-series, expert opinion and studies without validated outcome measures. International 
Myositis Assessment and Clinical Studies (IMACS) group, is currently validating measures of 
disease activity, damage and response to treatment to allow for better drug surveillance and 
assessment.[118] 
Even today, high dose corticosteroids are conventionally used as first-line therapy and the 
majority of IIM patients at least improve with corticosteroid treatment.[117, 119, 120]. Due to 
all the long-term side-effects of steroids, the usage of non-steroid immunosuppressive 
treatment has become the standard level of care over the recent years. Methotrexate and 
Azathioprine are the drugs of chose as steroid-sparing medication.[121] Recent studies have 
shown that patients treated initially with azathioprine have better survival.[97, 104]  
Cyclosporine and Tacrolimus are sometimes utilized in patients with ILD in combination with 
corticosteroids.[122-125] Intravenous Immunoglobulins (IVIG) are used in rapid progressive 
severe myositis, especially when oesophagus is involved.[126-128] MMF, alone or in 
combination, has been shown successful in some cases in treating refractory PM/DM, also 
with ILD.[129-131] Cyclophosphamide is usually utilized in patients with severe disease and 
ILD, but concerns over the development of late malignancies has limited their use over the 
recent years.[124] One of the few randomized controlled trials on IIM has recently been 
published on Rituximab treatment.[132] Anti-TNF and Tocilizumab are currently being tested 
for efficiency and effect in treating IIM patients.  
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1.2 Sporadic Inclusion Body Myositis (sIBM). 
1.2.1 History of sIBM 
 Sporadic inclusion body myositis (sIBM) was first acknowledged as an entity separate from 
PM in 1971[133], but descriptions of histopathological and clinical features compatible with 
sIBM exist from the mid-60s.[134, 135]Traditionally, sIBM has been regarded as one of the 
three IIM and it may account for 30% of IIM cases.[33, 136] There is, however, growing 
evidence that the disease mechanisms in sIBM differ from PM and DM, [33] and represent a 
distinct separate entity with both inflammatory and degenerative changes.[137-140]
1.2.2 Clinical features of sIBM: 
This disorder   is characterized by slowly progressive, asymmetric, atrophy and weakness of 
both proximal and distal muscles, most prominently affecting the finger and wrist flexors and 
quadriceps. [141] Recent, large-sized clinical studies provide further support to the notion that 
the muscle disease pattern in sIBM is highly characteristic, with asymmetric distribution, slow 
progression of proximal and distal weakness and predominant involvement of the quadriceps 
and finger flexor muscles.[137, 142] Dysphagia appears to be very frequent and can be 
disabling and potentially life-threatening. [22, 23, 137]. Unlike PM and DM, sIBM is 
unresponsive to immune-modulating treatments. Hence, even though involvement of other 
organs than muscles is rare, sIBM has an end-stage of major disabilities.[142, 143]
1.2.3 Classification criteria sIBM
Since we do not know the cause or pathogenesis of IBM, there is no “gold standard” for the 
diagnosis. There is an ongoing debate on how sIBM should optimally be diagnosed. The first 
widely used diagnostic criteria for sIBM, suggested by Griggs et al. in 1995, were primarily 
based on histology findings.[144] In 1997,  the European Neuro-Muscular Centre (ENMC) 
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produced new criteria set which allowed for sIBM diagnosis in cases with highly suggestive 
clinical features, but incomplete histology(Table 7) .[145] Diagnostic criteria primarily based 
on clinical findings were first proposed by Hilton-Jones in 2009.[146] These criteria only 
required that histology was supportive, and not inconsistent with sIBM.[146] The new ENMC 
diagnostic criteria (2011 ENMC IBM Research Diagnostic Criteria)[147] also emphasize 
clinical phenotype rather than pathology, and additionally, aim to allow for earlier diagnosis 
than previous criteria sets (Table 8A,B and C).
Table 7. ENMC 1997 criteria [145]
Clinical items
1 Proximal weakness 
2
Distal weakness (forearm muscles, particularly finger flexors, or wrist flexors more 
than wrist extensors)1
3 Slowly progressive course 
4 Sporadic disease 
5 Age above 30 years at diagnosis 
6 Disease duration above 6 months 
Histological items 
7 Mononuclear inflammatory infiltrates with invasion on non-necrotic muscle fibres. 
8 Rimmed vacuoles 
9 Ultrastructure tubulofilaments (protein accumulations) of 16-21nm 
Scoring of ENMC criteria;
 Definite sIBM 1,2,3,4,5,6,7,8 or 1,3,4,5,6,7,8,9 
 Probable sIBM 1,2,3,4,5,6,7 or 1,3,4,5,6,7,8 
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Table 8, Overview of the 2011 ENMC  IBM Research Diagnostic Criteria
A Clinico-pathologically defined sIBM 
Clinical and laboratory features Pathological features
1 Duration >12 months All of the following  
2 Age at onset >45 years 1 Endomysial inflammatory infiltrate 
3 Knee extension weakness စhip flexion weakness 
and finger flexion weakness > shoulder abduction 
weakness
2 Rimmed vacuoles 
4 Serum CK no greater than 15×ULN 3 Protein accumulation or 15–18 nm 
filaments 
B Clinically defined 
Clinical and laboratory features Pathological features
1 Duration >12 months One or more, but not all of; 
2 Age at onset >45 years 1 Endomysial inflammatory infiltrate 
3 Knee extension weakness စhip flexion weakness 
and finger flexion weakness > shoulder abduction 
weakness
2 Rimmed vacuoles 
4 Serum CK no greater than 15×ULN 3 Protein accumulation or 15–18 nm 
filaments 
C Probable sIBM 
Clinical and laboratory features Pathological features
1 Duration >12 months One or more, but not all of; 
2 Age at onset >45 years 1 Endomysial inflammatory infiltrate 
3 Knee extension weakness စhip flexion weakness 
or finger flexion weakness > shoulder abduction 
weakness
2 Rimmed vacuoles 
4 Serum CK no greater than 15×ULN 3 Protein accumulation or 15–18 nm 
filaments 
The clinically defined and Probable IBM only require one of the following findings on muscle 
biopsy; endomysial inflammatory infiltrates, up-regulation of MHC-1, or rimmed vacuoles. 
The clinically defined IBM require stricter clinical findings, especially when it comes to 
definition of distal muscle weakness i.e.: knee extension weakness > hip flexion weakness 
and finger flexion weakness > shoulder abduction weakness. 
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The probable IBM diagnosis is the same as the clinically defined IBM, but requires less strict 
definitions of distal muscle weakness; knee extension weakness > hip flexion weakness or 
finger flexion weakness > shoulder abduction weakness. 
1.2.4 Aetiology and pathology sIBM: 
When sIBM was first described, it was also regarded as a primary immune-mediated, but 
recent data have more suggested that the disease is caused by degenerative processes [148]. In 
sIBM, clonally expanded CD8 positive cytotoxic T cells invade muscle fibre that express 
MHC-class I antigens, which leads to fibre necrosis via the perforing pathway and vacuoles 
formation with amyloid deposits coexisting with the immunological features[2] Muscle 
biopsy characteristically reveals endomysial inflammation infiltrates and lymphocyte invasion 
in morphologically normal myocytes and degeneration with small groups of atrophic fibres, 
eosinophilic cytoplasmic inclusions and muscle fibres with one or more rimmed 
vacuoles.[149]. However, it is important to note that any given sIBM biopsy may lack any of 
these characteristic microscopic features. [150]
Genetic studies on the Major Histocompatibility Complex (MHC) have discovered a 
susceptibility region in the 8.1 ancestral haplotype in a 172 Kb region near the HLA-
DRB1*0301 (HLA-DR3) allele. This region contains 3 genes; BTNL2, HLA-DRA and HLA-
DRB3.[151] Further studies are ongoing to map the susceptibility gene. However it might be 
possible that epistatic interaction at this site is important in determining susceptibility, as it 
appears that the HLA-DR1/DR3 combination is a higher risk for developing sIBM, rather 
than HLA-DR3 homozygotes.[152]   
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1.2.5 Epidemiology sIBM 
Few studies on the epidemiology of sIBM have been performed. The first, large chart review 
study on sIBM was a nationwide collaborative cross-sectional study performed in the 
Netherlands in 1999. [153] The study applied the 1997 ENMC criteria and identified 76 
patients with sIBM; giving an estimated population prevalence of 4.9/ 1 000 000. [153] The 
authors reported that prevalence was probably underestimated, but to date, there are no 
equivalent European studies for comparison. Three Australian surveys, all based on local 
histopathology criteria, reported sIBM prevalence ranging from 9.3 to 50.5 per million.[154-
156] In Japan, the prevalence of sIBM, judged by the combination of several sIBM criteria 
sets [144, 146, 150] was estimated to 9.8 per million in 2003, with an increasing prevalence 
over the last decade.[157, 158] In contrast, a recent biopsy-register study from Turkey 
reported only 1 sIBM case per million, possibly reflecting differences in sIBM prevalence 
across genetic backgrounds.[159] 
1.2.6 Mortality and morbidity in sIBM. 
Knowledge on survival and mortality in sIBM is more limited. Long-term follow-up studies 
from Europe have not found reduced life expectancy. [160] In contrast, a recent multi-national 
study on selected patients, with no detailed case definition data available, reported increased 
mortality, with an estimated SMR of 6.58 for patients aged 41+, and 4.82 for patients over 70. 
[161] One of the few long-term follow-up studies  recently published did not find a higher 
mortality rate or lower life-expectancy compared to age/sex matched normal background 
population, but the study did however find different causes of death in the sIBM cohort; 
mostly related to infection, respiratory complications-aspiration, cachexia and malnutrition 
and a higher incidence of cardiac associated deaths.[142] The study concluded that the 
outcome in sIBM is one of major disabilities at the end stage of the disease due to extensive 
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muscle weakness[142] The mean decline in strength was 3.5 and 5.4% per year according to 
the manual muscle testing and quantitative muscle testing, respectively. This decline was 
most pronounced in the lower legs, which were also the weakest extremities. Life expectancy 
was normal at 81 years, but activities of daily life were clearly restricted. At follow-up, all 
patients were found to be using a wheelchair, 47% being completely wheelchair-bound.[142] 
1.2.7 Cancer risk sIBM 
Population-based retrospective cohort studies have consistently confirmed an increased risk of 
malignancy in the setting of DM and PM and recently in sIBM. A recent retrospective study 
on biopsy-proven IIM cases from Victoria, Australia reported increased cancer risk across all 
IIM subsets, including sIBM (Table 6). This study found the proportion of sIBM patients 
having cancer to be 23% and the SMR 2.4 CI 95% (1.4, 49) [111]  There are in addition 
several case-rapport supporting these findings [162-164] On the other hand, a 12 year long-
term follow-up study from the Netherlands did on the contrary find a smaller incidence of 
malignancy in the sIBM cohort compared to the background population.[142] 
1.2.7 Treatment sIBM 
To date no efficient treatment of sIBM exists, there are however possible promising new 
drugs being tested.[165, 166] There is also no standard course of treatment.  The disease is 
generally unresponsive to corticosteroids and immunosuppressive drugs.[137, 167-
173]  Some evidence suggests that intravenous immunoglobulin may have a slight, but short-
lasting, beneficial effect in a small number of cases, but the effect has not been shown to 
sustain over time.[169, 174-179]  Physical therapy may be helpful in maintaining mobility. 
Other therapy is symptomatic and supportive. 
32

2. AIMS of the study: 
Main aim:
To establish baseline estimates of the occurrence, disease characteristics, survival and cancer 
risk in IIM patients in South-east Norway in the period from 2003-2012.  
Specific aims: 
x Determine the point prevalence and clinical characteristics of a large unselected 
PM/DM cohort. 
x Determine point prevalence and clinical characteristics of sIBM in Southeast Norway 
by 31.12.2012 
x Determine the overall survival of the IIM patients living in Southeast Norway 2003-
2012. And to identify the causes of death and mortality hazard ratios. 
x To identify the cancer association and risk in all IIM patients 
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3. Methodological-considerations:
3.1 Study population and data collection: 
Norway is divided into five health-regions. The largest region is situated in South-east 
Norway and consist of 10 counties with 2 642 246 inhabitants (by 31.12 2012) and includes 
the largest cities in Norway and is mostly urban/suburban dwellings (Figure 1). There are 10 
main hospitals in the South-east health region; of which Oslo University Hospital (OUH), is 
the largest and serves as the primary hospital for the whole of Oslo (with 600 000 inhabitants) 
and tertiary referral centre for all the 10 counties in the region.
In Norway, patients with connective tissue diseases, including IIM are followed by the 
secondary health system at public hospitals. PM/DM patients are mostly cared for by 
rheumatologists, and sIBM are seen by either neurologists and/or rheumatologists. Since 
1999, all patients contacts in the secondary health system were electronically registered by 
10th revised version of the International Classification of Disease (ICD-10) codes. The IIM 
cohort was selected from this denominator population and consisted of every person who 
fulfilled the study inclusion criteria for PM/DM and sIBM (see below).
The South-east Norway health region was selected as the denominator population for this 
IIM-study, due to several factors. Firstly it is the largest health region and consists of 
approximately half of Norway’s population. Hence it produced a large-sized, unselected 
PM/DM cohort. Secondly, Oslo University Hospital (OUH) is the only specialized centre for 
connective tissue diseases and vasculitis in Norway, and it has the main focus on IIM  in 
Norway. We therefore believe that most of the PM/DM patients have been referred at least 
once to this tertiary centre. This fact is confirmed by all intermediary analyses  which show 
that almost all the PM/DM patients in the study cohort were captured more than once, either 
at more than one site (i.e. locally and at the OUH referral centre) and/or at more than one time 
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point during the study period.  Thirdly, due to labour-intensive approach we utilized and the 
fact that the approach was very time-consuming and involved all departments at all hospitals 
in the health region, we did not have the capacity to assess the whole of Norway. But we do 
believe that South-east Norway cohort gives a good and sound estimate and picture of the IIM 
patients in Norway. We chose to screen all patients registered with relevant ICD-10 codes at 
least once in the period from January 2003 to December 2012. The rationale behind this long 
acquisition period was for patients to have enough time to develop a full clinical picture. We 
found this especially important in the sIBM cohort, which has an insidious nature and slowly 
developing clinical picture.
Figure 1 Map over South-east Norway and its 10 counties
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3.2 Study inclusion criteria PM/DM: 
We decided to include two sets of PM/DM criteria; the Peter& Bohan and Targoff criteria 
(Table 9) The Peter & Bohan criteria were selected because they are still considered “gold 
standard” for PM/DM and the basis for much of previous IIM research. We did in addition 
include the Targoff criteria because they in also include MRI and MAA criteria and has 
recently been evaluated to be the most sensitive of existing IIM criteria.[37] A limitation with 
the Targoff criteria is that early PM cases without all typical biopsy, EMG or MRI findings 
may be missed out and the patients may not fulfil the criteria at the first visits. Moreover, the 
Targoff criteria require many tests to be performed, which could lead to an underestimate of 
the prevalence due to missing data. The first limitation was tried overcome by having a long 
acquisition period. The rationale for exclusion of overlap syndromes is the wish to look at 
pure IIM patients. There are existing Systemic Sclerosis, MCTD and SLE cohorts at OUH 
being looked at separately. 
Table 9 Study inclusion criteria PM/DM 
A Disease classifiable as probable or definite adult PM or DM by the Peter & Bohan 
criteria and/or the Targoff criteria [27, 28] 
B Age above 18 years at disease onset. 
C Registered in the Norwegian Central Register with a home address in South-east 
Norway between January 1st 2003 and December 31th 2012. 
D Myositis not explained by the presence of another connective tissue disease (i.e. 
SLE, Systemic Sclerosis or Mixed Connective Tissue Disease). 
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3.3 Study inclusion criteria sIBM: 
There is an ongoing debate on how sIBM should optimally be diagnosed .We chose to utilize 
the 1997 ENMC criteria (Table 7). The rationale behind this, was that the 1997 ENMC 
criteria was the only one that had been utilized in the  previous European epidemiological 
sIBM study that exists.[153] The 1997 criteria was also one of the first criteria to allow for 
sIBM diagnosis in cases with highly suggestive clinical features, but incomplete histology 
.[145]  The new ENMC diagnostic criteria (2011 ENMC IBM Research Diagnostic 
Criteria)[147] (Table 8 A, B and C) was published in 2013 after the end of the study 
inclusion. The new criteria emphasize clinical phenotype rather than pathology, and 
additionally, aim to allow for earlier diagnosis than previous criteria sets. We found it 
interesting to assess and compare these two sets and to validate the new criteria. But there 
were difficulties and limitations due to the retrospective assessment of the 2011 criteria. The 
problems were mostly related of the incomplete data and missing information on muscle 
power, function and testing. Not all patients had been assessed by Physiotherapists for Manual 
Muscle Tests (MMT) or Functional Index 2 (FI2) or MRC (Medical Research Council) scale 
by neurologist. We did have information about distal muscle involvement, but not always 
which specific muscles that were affected. This led to that most patients were classified as 
probable sIBM (table 8 C). 
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Table 10; Overview of study inclusion criteria for sIBM 
A Disease classifiable as sIBM by the 1997 ENMC sIBM criteria, and /or the 2011 
ENMC IBM Research Diagnostic Criteria.[145, 147]
B Exclusion of PM or DM as possible diagnoses
C Inclusion body myositis not explained by familial disease.
D Patient registered in the Norwegian Central Population Register with a home address 
in South-East Norway between January 1st 2003 and December 31th 2012
3.4 Case finding strategy: 
Two major acquisition routes were utilized to identify all the adult PM/DM and sIBM patients 
(1) extensive searches across multiple ICD-10 codes (Table 11) to catch all potential IIM 
patients, followed by chart review of all of the encoded patients (2) and for sIBM patients 
retrospective review of all muscle biopsy reports that had been encoded with inflammation.
We applied a wide range of relevant ICD-10 codes, over a long acquisition period, to ensure 
that all the IIM cases living in the study area were captured (Table 11).The rationale behind 
the chosen ICD-10 codes were to also catch sIBM patients which do not have a separate ICD-
code. Initially, the database at OUH was screened across all the ICD-10 codes selected (Table 
11): [180]. The OUH data showed that no sIBM cases were given G-codes. Only one PM 
patient received a G-code (G72.9), but this patient was diagnosed in 1993. Hence, the 
searches undertaken at the other South-East Norway hospitals, was limited to the six M33 and 
M60 codes.
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Table 11, ICD-10 codes utilized in IIM search 
ICD-10 code Description ICD-10 code Description 
M33.1 Adult DM G72.4 Inflammatory myopathy, not 
specified 
M33.2 PM G72.8 Other specified myopathies 
M.33.9 Unspecified PM/DM G72.9 Unspecified myopathy 
M60.1 Interstitial myositis G73.7 Myopathy associated with
diseases classified elsewhere 
M60.8 Other, specified myositis   
M60.9 Unspecified myositis   
For the sIBM part of the study, all muscle biopsy reports obtained between 2003 and 2012 
were re-reviewed. These muscle biopsies were initially examined by five neuropathologists at 
two laboratories in Oslo (Rikshospitalet and Ullevål) and one in Tromsø. From 2010, the two 
laboratories in Oslo were merged within the Department of Pathology, OUH. For our review, 
all the muscle histology reports encoded with inflammation in the Systematic Nomenclature 
of Medicine (SNOMED) code system were reviewed by a neuropathologist (EAA), and the 
following parameters were recorded; endomysial inflammatory infiltrates, lymphocyte 
invasion in vital myocytes, rimmed vacuoles, MHC 1-expression (any and general), and the 
presence of inclusion body filaments at ultra-structural examination. The neuropathologist had 
access to muscle biopsy referral information and the pathology reports produced by the five 
other neuropathologists, but not the clinical charts and patient journals.
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3.5 Patient characteristics and disease measures: 
Predefined registration forms were used to record hospital chart data on the patients identified 
by the ICD-10 based case finding strategy. All information was imported to the Microsoft 
Office Access database after scanning with Cardiff Teleform 10.1 Software.  
Age, gender, time of symptom onset, time of disease onset (defined as the date when IIM was 
first diagnosed) and patient observation period was recorded. The observation period was 
terminated 31th of December 2012 or at the time of death. Disease duration was defined as 
the time from diagnosis to the end of the observation period (Table 12).  
Table: 12 Demographic variable and disease characteristics 
Date of birth, first and last name and gender 
Residential town and county 
Diagnosis ICD-10 and name of diagnosis (PM, DM, sIBM or unspecified) 
Date of first and last hospital contact and name of hospital 
Year of first symptoms 
Year of diagnosis 
Date of death and cause of death 
Data source (hospital and ward) 
Clinical parameters were recorded at disease onset and cumulatively during follow-up (Table 
13). ; The myalgia frequency were scored as positive when a doctor reported it as an observed 
sign or as a subjective symptom by the patient. The interpretation of this symptom is 
subjective and may have led to an overestimation, especially due to retrospective design and 
interpretation of subjective data by, in many cases, a single observer. Arthritis needed to be 
confirmed by doctor; either clinically, by ultrasound or MRI imaging. 
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The following laboratory parameters were also recorded; ESR (Erythrocyte Sedimentation 
Rate), anti-nuclear antibodies (ANA), MAA (anti-Jo-1, anti-PL-7, anti-PL-12, anti-SRP and 
anti-Mi-2) and anti-SSA. Imaging data and functional lung and heart data were recorded 
(Table 14) We also recorded data on the following immune-modulating treatments; 
corticosteroids, Methotrexate, Cyclophosphamide, Cyclosporine A, Rituximab, intravenous 
immunoglobulin, Mycofenolate mofetil, Tacrolimus, Hydrochloroquine and anti-TNF 
treatment.  Treatment was recorded as received, not received or missing data.All available 
chart data on malignant disease, at any time during the life of the patient, was also recorded.
Table.13 Clinical parameters recorded at debut and during follow-up. Parameters were 
recorded as present, absent or missing data. 
Symptoms  Symptoms and other chronic diseases 
Arthritis / Arthralgia Dyspnoea 
Mechanical hands Cough 
Dysphagia  Muscle weakness 
Calcinosis cutis  Myalgia 
Gottrons signs/ rash Fever, “flu-like symptoms  
Heliotrope rash Cancer 
Sicca phenomenon Heart disease  
Raynaud Pulmonary disease not related to IIM 
Other connective tissue disease or chronic disease 
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Table.14 Imaging and investigations recorded as present, absent or missing data:  
Plain radiology of the lungs Present/absent or missing data 
High Resolution Computed 
Tomography of the lungs (HRCT 
thorax)
Date of first HRCT thorax, date of first 
sign of ILD, date of last HRCT thorax 
undertaken
Dynamic studies of the Oesophagus Date of examination(s) Dysmotility: 
yes/no/missing data 
Pulmonary function testes Date of last examination. FVC, FEV1, 
DLCO    in numbers and percentages 
Echocardiography Pathology; yes/no
ECG Pathology; yes/no
3.6 Recording of patient data and items assessed by the Targoff criteria:
Detailed recording of the P&B and Targoff criteria items was performed. Items were defined 
as positive by the following rules; (1) Proximal muscle weakness: described by a specialist 
(rheumatologist or neurologist) during clinical examination as weakness (and sometimes 
weakness) involving thigh and/or shoulder/neck muscles. Weakness was sometimes also 
quantified by the Medical Research Council (MRC) scale (0-5) and/or Manual Muscle 
Testing (MMT) performed by physiotherapists. (2) Elevated serum muscle enzymes- creatine 
kinase (CK) ,( 3) EMG/neurography described as myopathy by neurophysiologist. (4) muscle 
histology compatible with IIM (5)  typical DM rash- Gottrons papules or sign and/or 
Heliotrope rash. (6) Positive MAA (anti-Jo-1, anti-PL-7, anti-PL-12, anti-SRP and anti-Mi-2) 
by immune blotting or ELISA. (7) muscle MRI findings compatible with myositis, as 
described by a radiologist.  We chose to register a large number of clinical information and 
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patient characteristic in order to map most of the clinical characteristics and outcomes as 
possible. To obtain the DM diagnosis the patient needed to have descriptions of a rash 
recorded by a doctor compatible with Gottron`s papules or sign and/or Heliotrope rash. In our 
study we did not have any patients that only exhibited V or Shawls signs alone without 
Gottrons signs/papules or Heliotrope rash.  Patients with a muscle biopsy compatible with 
DM without a skin rash, was not classified as DM  and patients with a muscle biopsy 
compatible with PM, but with Gottron`s sign or papules and/or Heliotrope rah were classified 
as DM.
Retrospectively, we wish that a more detailed description of muscle power had been noted 
and defined. But unfortunately this study has a retrospective design and hence has several 
weaknesses in that data collection is undertaken on medical records and not by standardised 
definitions. We did gather a lot of radiological and treatment data, which has not yet been 
analysed. These data will be handled in the near future.
. 3.7 Recording of patient data and items assessed by the 1997 and 2011 ENMC criteria 
for sIBM. 
Scoring of the clinical and histopathology items according to the 1997 and 2011 ENMC 
criteria was performed as follows (Table 14); (1) Proximal muscle weakness: described  by a 
specialist (rheumatologist or neurologist) during clinical examination as weakness (and most 
often also atrophy) involving thigh and/or shoulder/neck muscles. Weakness was quantified 
by the Medical Research Council (MRC) scale (0-5) and/or Manual Muscle Testing (MMT) 
performed by physiotherapists. (2) Distal muscle weakness: described by a specialist during 
clinical examination as weakness in the finger flexors and/or the combined presence of 
reduced grip strength and atrophy of ulnar forearm muscles. Distal weakness was not 
quantified, but registered as present or absent. (3) Knee extension weakness, described by a 
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specialist and quantified by MRC and/or MMT. (4) Slowly progressive course; chart 
description of weakness progressing slowly over years. (5) Sporadic disease; no chart 
information on familial clustering. (6) Total disease duration over 12 months. (7) Age of 
onset; above 30 years for 1997 criteria and above 45 for 2011 criteria. (8) Maximum CK 
levels, recorded from chart data. (9) Muscle biopsy parameters recorded from pathology 
reports; endomysial inflammatory infiltrates, lymphocyte invasion in vital myocytes, rimmed 
vacuoles, MHC 1-expression (any and general), the presence of inclusion body filaments at 
ultra-structural examination.(Table 14). The ENMC criteria include protein accumulation 
staining (p62, Congo red, TDP-43), unfortunately only a simple Congo stain are available at 
the pathology departments involved. Simple Congo stain does unfortunately not have a great 
place in the search for inclusions (probably not sensitive enough).This may have led to an 
underestimation of inclusion body filaments at ultrastructure examination. 
OUH, Rikshospitalet, uses a routine diagnostic process, involving sectioning large quantities 
of deeper sections from the frozen tissue (in search for inflammatory infiltrates and rimmed 
vacuoles). This may have influenced the number of rimmed vacuoles found in each biopsy. In 
addition, toluidine blue stained sections from glutaraldehyde fixated muscle, are also routinely 
examined by light microscopy, which may also have improved the chance of finding rimmed 
vacuoles. Unfortunately, we did not formally record the number of sIBM patients that were 
initially diagnosed as PM or unspecific myositis, but our impression from the chart review 
process was that approximately 1/5 of the sIBM patients had another myositis diagnosis 
before they were diagnosed with sIBM. 
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3.8 Assessment of Standard mortality rate (SMR) and survival rates:
Every IIM patient was matched with 15 healthy controls drawn from the national population 
registry via Statistics Norway. The matching included the same sex, area of residence, month 
and same year of birth. Vital status at January 1st, 2013, was provided for patients and 
controls by the National Population Registry. Causes of death were obtained from the Cause 
of Death Registry, coded with ICD-codes, in addition patients journals were searched for 
death certificates and clinical information in addition to autopsy reports. The case-control 
approach to survival analysis in IIM has not been utilized previously, and we found it 
interesting to assess the accuracy, compared to that of life-tables. When matching controls 
from the national population registry via Statistics Norway, we encountered problems with the 
identity of two patients which had been operating with two different names and personal 
identification numbers. We decided to exclude these all together from the last study, leading 
to a total of 326 IIM patients included in the survival and cancer-research. 
3.9 Assessment of causes of death:
Using the personal identification numbers, we were able to identify every diseased person and 
all the reported causes of death in the IIM cohort between 01.01.2003 and 31th of December 
2012. Causes of death were identified by manual chart review of medical charts, death 
certificates and autopsy and from codes from the Cause of Death Registry. When there was 
discrepancy between information, data from the medical charts were used. The cause of death 
in the control group was given by Statistics Norway. In the IIM group causes of death was 
classified as either as IIM related mortality or mortality unrelated to IIM. If there was no 
notification of the death-it was named unknown. 
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3.10 Assessment of Cancer in IIM cohort. 
The cancer registry, Norway provided data on cancer prevalence between 2003-2012 in the
IIM patients and their matching controls, coupled via their personal identification numbers.  
Time and place of cancer diagnosis, stage, type and metastasis, organ of origin, and if death
was related to cancer. Eight additional patients had received cancer diagnosis before 2003
and were identified during chart review and pathology reports. We included the latter eight to 
enable for the assessment of disease-related cancer +/-3 years the year of diagnosis.  The 
rationale for usage of 15 controls pr. patient was to have the most precise control group to 
compare, and we did not use life-tables. But when it came to rarer cancer-forms, with low 
prevalence in the population, we utilized life-tables in addition, to ensure a correct estimate. 
3.12. Statistical analysis. 
Statistical analysis was undertaken by SPSS, version 20/21 and STATA[181]. Descriptive 
statistics; continuous variables with normal distribution were presented as mean with Standard 
Deviation (SD) or 95% Confidence interval. Categorical variables were presented as numbers 
and percentages. Group differences were analysed by Student t-test (2-tailed, unpaired). 
Pearson’s Exact test and Chi Squared test was utilized for the comparison of independent 
groups of categorical data, significance level was p<0.05. Cumulative survival rates were 
calculated by the Kaplan-Meier method and significance was tested with the log-rank test. 
Survival curves were used to compare with the curves of the controls. Hazard rates were 
calculated by usage of SPSS Cox regression, survival and hazard plots. 
STATA was utilized when calculating SMR and SIR, and Incidence rate ratio, SMR pr. 1000 
person year. Mean time to death in years and Mean time from cancer to death in years were 
calculated using SPSS and STATA. STATA was also used when calculating 2,5 and 10 year 
survival.[181]
46

3.13 Legal and ethical aspects: 
The Regional Committee of Medical ethics in Southern Norway (REK sør), the Norwegian 
Ministry of Health (the Norwegian Patient Registry) and Privacy Policy Department at OUH 
have all approved this study with all aspects related to patient data recording and ethical 
aspects related to the handling of patient sensitive material.  
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4. Summary of results: 
Paper 1:
Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; -data 
from a large and unselected Norwegian cohort 
In this study we aimed at identifying all PM/DM cases over a 10 year period and to calculate 
the point prevalence on the 31st of December 2012. Furthermore; we wanted to map the 
clinical characteristics of the PM/DM patients identified and to compare the two patient 
groups. All hospitals in South-east Norway were screened for potential IIM-patients by ICD-
10 code searches.
The total number of cases identified by the code search was 3160. Manual chart review 
revealed that,   only 230 of these 3160 cases met the Targoff criteria (130 DM and 100 PM.) 
The point prevalence of PM/DM was estimated to be 8.7/ 100 00 (CI 95% 4.5, 11.2) with 
large variations seen between the counties. Calculated annual incidence rates based on 
retrospective data with their limitations ranged between 6/1 000.000 and 10/ 1000.000 across 
the study period. . 
The peak incidence for PM patients was between 60-69 years compared to 50-59 in the DM 
group. At diagnosis, the mean age of the PM patients was 56.0 years, higher than the mean 
51.6 years in DM. Mean time from symptom debut to diagnosis did not differ between the 
groups, but diagnostic delay above two years was more frequent in PM (29%) than in DM 
(14%), (p=0.005).
Chart information about clinical features at disease onset and during follow-up was recorded 
and cumulative frequencies estimated. Muscle weakness was present in 84% at disease onset 
and cumulatively in 97%. Dysphagia was quite rare at disease onset (23%), but increased to 
58% during follow-up. Dyspnoea, Raynaud`s phenomenon and mechanic hands were more 
frequent in DM than in PM (p = 0.002, P=0.009 and p=0.0000 respectively). We found that 
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DM patients had more extra-muscular features than PM. Pathological MRI findings were 
noted in 137/163 (84%) of the patients,
MAA was identified in 59% of DM patients and 41% of PM patients. The most commonly 
tested and detected MSA was anti-Jo-1, being present in 65/204 (28%) of the patients, 47/121 
(39%) in DM and 18/83 (22%) in PM. Correlation analyses showed correlations between anti-
Jo-1 and dyspnoea (unadjusted Odds ratio (OR) 7.7) arthritis (OR 7.5) and mechanic hands 
(OR 4.5).
 In conclusion, this study provides novel population-based data on the prevalence and clinical 
characteristics of PM and DM in Caucasians. Compared to previous studies, the prevalence 
and incidence rates are similar, but more strikingly are the number of anti-Jo and MAA 
positive patients in this cohort. 
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Paper 2
High prevalence of Inclusion Body Myositis in Norway; a population based clinical 
epidemiology study. 
In this study we aimed to identify all sIBM patients in south-east Norway and to calculate 
point prevalence on the 31st of December 2012. We did in addition want to assess clinical 
characteristics, gender differences and differences in follow-up-regimens and to assess 
imaging data. The ICD-10 based case finding and chart review process was done in 
conjunction with PM/DM (Paper 1) .In addition, a review of all muscle biopsies encoded with 
inflammation was performed by an experienced neuropathologist. All the potential sIBM 
cases identified were scored according to the 1997 ENMC criteria and later by the 2011 
ENMC criteria. Patient chart review and muscle biopsy reports showed that 100 of the 
patients identified by the case finding strategies met either the 1997 and/or the 2011 ENMC 
criteria for sIBM. The 1997 criteria were met by 92 patients, while 95 met the 2011 ENMC 
criteria. Retrospective chart review showed that all the patients had proximal muscle 
weakness and knee extension weakness. Distal weakness (i.e. finger flexor weakness) was 
described in 94/100 patients. The most frequent biopsy features were endomysial 
inflammatory infiltrates (in 92/97 patients) and rimmed vacuoles (91/97). Up-regulation of 
MHC 1 (of any degree) was described in78/95 patients, with generalized MHC1-up-
regulation in 61 biopsies. Electron microscopy was performed in 70 patients, and 16 of these 
had 15-18 nm tubulofilaments 
At diagnosis, the mean age of sIBM patients were 66.9 years, and mean time from symptom 
onset to diagnosis was 5.6 years. Male to female ratio was 1.5:1. Clinical characteristics 
showed no gender bias, except from dysphagia, being more common in women (94 %) than in 
men (65%).Serum auto-antibodies were frequent; with ANA in 37% and anti-SSA in 22%; 
with a female predominance.  
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The estimated point prevalence of sIBM in South-east Norway by the 1997 and 2011 criteria 
were thus similar at 33/1.000 000 and total 35/100 000 for the entire cohort on the 31th of 
December 2012.  Large differences between the individual counties in the area were noted.  
Estimated annual incidence rates of sIBM across the study period ranged from 2/1 000 000 to 
6/1 000 000. We identified that 24% of patients exhibited co-existing rheumatic diseases 
(24%), most commonly Sjøgren`s syndrome (10%) were exclusively followed by 
rheumatologists.. 
MRI of thigh muscles had been undertaken in 56/100 patients, and 88% had atrophy and 
oedema. Oesophageal dysmotility was recorded in 45/54 patients examined by this modality. 
In conclusion, we found a point prevalence of sIBM 7 fold higher than previous 
epidemiological studies from Europe, which may indicate that there might be an 
underestimation of sIBM in Europe and that there possible is a genetic link to this disorder. 
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Paper.3
Survival and cancer risk across an unselected and complete cohort of idiopathic 
inflammatory myopathy in south-east Norway.
In this paper, the PM/DM and sIBM cohorts described in Paper 1 and 2 were utilized 
for mortality and cancer risk analyses. The 326 IIM patients included (98 PM, 128 DM and 
100 sIBM) were matched to 15 controls with same the age, gender and residential area. The 
cohort and controls were coupled to the Causes of Death registry, Statistics Norway and 
Cancer Registry Norway. By the end of the study period, 87/326 patients had died. Mean time 
from diagnosis to death was shorter in DM (4.2 years) than in PM and sIBM.
 Mortality was primarily assessed by SMR. The highest SMR (2.6) was observed in DM. 
Stratification by time of diagnosis showed that SMR was significantly lower in DM patients 
diagnosed before 2003 (SMR 1.3) than in patients diagnosed from 2003 and onwards (SMR 
3.2). The same trend was seen in PM. Survival rates was calculated by Kaplan Meier Graphs 
and the test of equality of survival distribution verified that the survival of IIM patients were 
lower than that in matched controls (Log Rank (Mantel Cox) (p<0.000). 
2,5 and 10 year cumulative survival was also calculated separately by STATA. The most 
sticking differences were seen at 10 years, where sIBM appeared to have a poor outcome with 
42% cumulative survival, but the corresponding low survival in the matched controls show 
that this was an effect of old age at diagnosis. DM patients had a 55 % 10 year survival and 
the lowest age at diagnosis compared to 78% in their matching controls, compared to PM with 
60% 10 year survival and 82% in controls. 
Causes of death were related to IIM in 56/87 (64%) patients. In DM, nine patients died 
secondary to myositis-associated cancer compared to five and three in PM and sIBM, 
respectively. ILD/PH caused nine deaths in the DM group compared to none in the sIBM 
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group and five in the PM group. Aspiration associated deaths were mostly seen in sIBM. 
Mortality risk factors, calculated by Cox regression, found that mean age at diagnosis was 
associated with increased mortality across all three IIM subsets. Disease duration was 
protective in all patients (P=0.000), with a lower risk in patients surviving past the first years 
of diagnosis. Cancer was identified as a risk factor in all IIM subsets, with hazard rates (HR) 
of 9.0 (P=0.000) in DM, 2.7 in PM (P=0.013) and 2.5 in sIBM (P=0.025). Diffusing capacity 
for carbon monoxide (DLCO) <60% (a marker for pulmonary involvement) was associated 
with a 13 fold risk in PM patients and a 5 fold risk in DM patients. In DM, FVC < 70% was 
also associated, with HR 7.0. The frequency of anti-Jo-1 was very high in our cohort, but 
neither anti-Jo-1, nor MAA in total were associated with increased HR. 
Total frequency of cancer in the IIM cohort was 24% compared to 16% in the age- and gender 
matched controls. Standard Incidence ratio (SIR) for cancer was higher in DM (2.0) than in 
PM (1.3) and sIBM (1.0). Myositis associated cancers, defined as occurring +/- 3 years of 
diagnosis, were seen in 18 DM patients and11 PM patients, with a large peak at the same year 
as IIM diagnosis. Cancer types and frequencies differed between the disease groups. The most 
frequent encountered cancers in DM were lung and ovarian cancer. In PM, haematological 
malignancies were the most common cancer types.  
These findings show a higher mortality and cancer-association, especially in DM patients, but 
also in PM. There are high numbers of disease related deaths in this cohort, some of which are 
potentially preventable. 
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5.0 Discussion: 
5.1.1 What is the role of epidemiologic research in IIM?
In the resent years, the main focus of research in the field of IIM has been on genetic studies 
and molecular studies on Myositis Associated Autoantibodies (MAA). Updated and valid 
epidemiologic data about the true incidence, prevalence and mortality are still missing in most 
parts of the world. The difficulties that exist in the epidemiology of IIM are due to the rarity 
of the diseases, heterogeneous study populations and difficulties with classification.[1, 29, 75] 
The epidemiological studies to date are few in numbers and mostly undertaken in single 
centres on selected patients. The importance of epidemiological research should not be 
undermined, and their role is to establish the fundament for all clinical research and more 
basal scientific studies. Genetic studies and molecular research can never substitute clinical 
knowledge and data on occurrence and the outcome of IIM.  Hence, we believe that 
epidemiology is imperative in the understanding of the mechanisms of disease. 
5.1.2 What have our methodology approach taught us?
Our approach, we believe, differs some from previous IIM epidemiology studies on several 
important issues. We would like to highlight four points that may have influenced the results 
we obtained; 
1) The case finding strategy; we applied a wide range of relevant ICD-10 codes, over a long 
acquisition period, to ensure that all IIM cases living in the study area were captured. In the 
next step, which we think was absolutely critical, we performed data collection and reviewed 
all journals that met the ICD-10 codes involved. Notably, the recently published database 
studies, solely based on code-searches,[81, 82, 182] would in our case, most likely have 
increased the number of IIM cases dramatically. In fact, of the 3160 patients identified by our 
code searches, only 328 met the inclusion criteria. The sIBM study was undertaken in 
conjunction with the study on the other IIM (PM and DM), which gave us the opportunity to 
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search for sIBM, which does not have a specific ICD-10 code, across a wide range of relevant 
myositis and myopathy codes; and it forced us to actively select against the possibility of PM 
and/or DM diagnoses in every potential sIBM case. Reassuringly, intermediary analyses 
showed that almost all the IIM patients in the study cohort were captured more than once, 
either at more than one site (i.e. locally and at the OUH referral center) and/or at more than 
one time point during the study period. Finally, the frequency of missing data in the cohort 
was very low. 
2) The use of several classification criteria; we applied more than one set of classification 
criteria for all the three diagnoses.  In PM/DM, patients were classified by the gold standard 
Peter and Bohan in addition to Targoff to encompass MRI and MAA findings. By 
comparison, the Targoff criteria, increased the overall number of classifiable patients only by 
10%, but the frequency of definite cases were raised by 30%. In sIBM patients we utilized the 
1997 and recently published 2011 ENMC criteria, which had similar sensitivities, but did not 
capture exactly the same patients. 
3) The use of matched population controls for cancer and mortality analyses. 
These issues were approached by a cancer and mortality design with cases from unselected 
PM, DM and sIBM cohorts matched with controls of the same age, gender and residential 
area. Our mortality and cancer data captured by manual chart review was confirmed and 
extended by data sets from the Norwegian Cancer and Mortality Registries. With the use of 
15 age- and sex-matched controls pr. patient, instead of life-tables, we got a unique 
opportunity to directly compare data across all the mortality and cancer analyses. We did 
however also look at life table-statistics for rarer cancer-types.
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4) The Norwegian Health system, demographics and genetic homogeneity of the population;
our study has the main advantage that the Norwegian health system is ideal for 
epidemiological studies; by means of the Personal Identification Number that every 
Norwegian citizen receives. This means that there is no loss to follow-up in the population. 
The hospital care also has electronic data journals and good registries for Cancer and Causes 
of death. The Norwegian population is in addition small, approximately 5 000 000, with only 
10% of the population on non-European ancestry, which gives a very homogenous ethnicity, 
and the environment and climate is distinct and different from most other countries in the 
world. These properties give a good opportunity to get reliable and sound epidemiologic data 
and the possibility for novel knowledge due to the homogeneity of the population.
.
5.1.3 Have our findings added new knowledge on IIM?  
 In paper 1; we found that the mean age of the PM patients at diagnosis, was 56.0 years, 
higher than the mean 51.6 years in DM. We have considered that maybe some PM patients in 
reality suffer from sIBM due the higher mean age at diagnosis and peak incidence, but due to 
the long follow-up period, we believe that most patients were given the right diagnosis. 
We found that Pathological MRI findings were noted in 84% of the patients, while positive 
MSAs were identified in 59% of DM patients and 41% of PM patients. And hence give the 
impression that MSA and MRI findings are important tools in diagnostics of PM/DM.
The most commonly tested and detected MSA was anti-Jo-1, present in 28% of the patients, 
39% in DM and 22% in PM, these numbers are different from previous studies were anti-Jo-1 
is more prominent in PM patients. We speculate in that our choice of DM definition, may 
have influenced this number, because patients with muscle biopsies compatible with PM with 
a rash, were given DM diagnosis if the rash was Heliotrope and/or Gottron`s. The observer 
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may also have interpreted the rash associated with ASS as DM, a mislabelled the patient. 
However the results are interesting.
In Paper 2;
In our sIBM cohort, detailed review of the patient charts and muscle biopsy reports showed 
that 100 of the patients identified by the case finding strategies met either the 1997 and/or the 
2011 ENMC criteria for sIBM. The 1997 criteria were met by 92 patients, while 95 met the 
2011 ENMC criteria. The patients that were excluded from the 2011 criteria set were all under 
the age of 45 at diagnosis and the eight patients that did not fulfil any of the 1997 criteria sets, 
had rimmed vacuoles, but not endomysial inflammatory infiltrates. The differences in 
numbers of patients fulfilling the criteria sets were not large, but it could be argued that the 
2011 criteria would benefit from lowering their age limit at debut. Notably, 79 of the 100 
sIBM patients would have met the original Griggs criteria. 
Serum auto-antibodies were frequent in sIBM; with ANA in 37% and anti-SSA in 22%; with 
a female predominance. The results indicate that an immunological process is involved. We 
found a higher frequency of dysphagia amongst the female sIBM patients. The differences in 
symptoms of dysphagia may be subjective. We did not correlate these to radiological findings, 
which would have been a more objective way of measuring this. 
Our observations show a much higher prevalence of sIBM than previously described and may 
support the notion that sIBM is genetically influenced. The large differences seen between the 
counties may indicated that there still are some patients that remain undiagnosed, possibly 
reflecting different density of specialists.
We identified that 24% of patients exhibited co-existing rheumatic diseases (24%). This 
indicates that patients with sIBM should be screened for other rheumatic diseases, especially 
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Sjøgren, because these patients may have a different course of disease and response to 
treatment. 
The high number of findings on patients examined by MRI and radiological studies of the 
oesophagus, may indicate that these imaging modalities are useful in investigating this 
disorder,
In paper 3: Causes of death were related to IIM in 56/87 (64%) patients. The main causes of 
disease-related deaths were cancer, ILD and/or secondary PH in PM/DM and oesophageal 
associated deaths in sIBM. The findings indicate that screening for cancer, pulmonary 
complications and oesophageal involvement are vital. And that some of the deaths are 
potentially preventable. When calculating hazard ratios, disease duration was protective in all 
patients (P=0.000), with a lower risk in patients surviving past the first years of diagnosis. 
These findings indicate that the majority of deaths occur during the first years after diagnosis. 
And this point should be elaborated and kept in mind in newly diagnosed patients.  
Myositis associated cancers, defined as occurring +/- 3 years of diagnosis, were seen in 29 
IIM patients, with a large peak at the same year as IIM diagnosis. Cancer types and 
frequencies differed between the disease groups. These findings show a cancer-association 
with DM and PM diagnosis and that the cancer types these patients encounter, are different to 
the matched control population. We do not see a clear cancer association in sIBM patients. 
We do also want to mention that utilizing +/-3 year of diagnosis time window for sIBM 
patients, may be misleading, because of the diagnostic delay of 5.6 years seen in this cohort. 
But the symptom debut is hard to define due to the insidious nature of this disease. 
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5.1.4 Will serology-defined phenotypes replace the traditional PM/DM classification? 
During the recent years discovery of several new MAA has become potential tools to aid 
diagnosis, prognosis and therapeutic considerations in patients with IIM.[183, 184] The novel 
MAA are still being tested and their complete role is yet unknown. There is a debate that 
these can be utilized as tools for subgrouping patients and for better understanding of 
prognosis and outcome. Approximately half of the patients in our IIM cohort, have recently 
participated in the testing of novel MAA (Sanner et al, unpublished data). Testing of sera with 
two myositis line immunoassays were undertaken on juvenile dermatomyositis patients (JDM, 
n=68), adult IIM patients (n=152), disease controls (n=123) and healthy controls (n=30). The 
two immunoassays; A1 covering six recently discovered MAAs (MDA5, TIF-1g, NXP2, 
SAE1/2, HMGCR and Mup44), and assay A2 with established MAAs (Jo-1, PL-7, PL-12, EJ, 
OJ, SRP, Mi-2, PMScl 75/100 and Ku) were utilized. Results show that all the six recently 
described MAA were recognised by adult IIM . Positive response to one or more A1 antigens 
was identified in 18% (27/152) of adult IIM , while A2 assay responses were seen in 62% of 
adult IIM. In adult IIM, anti-Mup44 was present in 6/19 patients (32%) with inclusion body 
myositis and 5/42 Polymyositis patients, three of these five were >70 years and therapy 
resistant. Anti-HMGCR was positive in four adult IIM (one with previous statin exposure). 
Three adult IIM had detectable anti-NXP-2 reactivity. Anti-MDA5 antibodies were seen in 
three adult DM patients, antibodies against SAE-1 were noted in three and anti- SAE-2 was 
identified in two DM patients.
ǡ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5.1.5 What does the higher prevalence of sIBM in Norway tell us?   
In our current study, multiple acquisition routes were applied to identify all the sIBM cases in 
South-East Norway over a 10-year period. With this strategy, we estimated the point 
prevalence of sIBM in Norway at study end to 33/1.000 000 by the 1997 and 2011 ENMC 
criteria (35/ 1.000 000 total). This estimate is substantially higher than previous European 
estimates. [79, 153, 159]  
The contingency of familial or hereditary cases being included as sIBM, due to the lacking 
knowledge, might be a possibility.  Another potential cause of an overestimation could be the 
usage of the recent published  2011 ENMC criteria[147] which is  not extensively validated to 
date. It could be debated that there might be an overestimation due to the 2011 criteria’s larger 
focus on clinical, rather than pathological findings. 
Atypical PM or other rare neurological myopathies are other differential diagnosis which 
might have led to a overestimation, especially since the  mean age at diagnosis in our PM 
cohort is higher than seen in many other studies.[180] But this notion should have been 
overcome by the 10 year follow-up of clinical picture and the notion that we discussed each 
case on a one to one basis in collaboration between neuropathologists and rheumatologists. 
Approximately 1/5th to 1/6th (15-20) patients did not initially fulfil the criteria, due to either 1) 
clinically lacking of distal weakness, especially finger flexor weakness, and these features 
became apparent over time. 2) The histopathology was initially not compatible with sIBM, 
but on re-biopsy the findings became apparent. 
Another fact that undermines this is that 98% of patients classified with sIBM exhibited 
rimmed vacuoles in muscle biopsies, which is in contrast to other studies which exhibit a 
significantly lower percentage of patients to have rimmed vacuoles on muscle biopsy. This 
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fact might even lead us to believe that the prevalence of IBM in Norway is even greater than 
we have estimated? 
Another suggestion for the much higher prevalence of sIBM in the Norwegian population 
may be genetic; a strong genetic influence by the MHC class II region has been reported in 
several inflammatory rheumatic disorders, however in many studies with different results. 
This is possible because of the actual differences in prevalence between distinct ethnic 
groups. Previous studies have shown that the HLA DRB1*03 allele is common in 
Scandinavia, but extremely rare in Japanese.[185] The exact population frequencies of Class 
II MHC alleles, HLA DRB1* 0301 in Norway, calculated from healthy controls in the bone-
marrow registry is 13.1%, the same figure was recently seen in this study from Norway. [186] 
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5.1.6 Has mortality changed over the last decades?      
Before the area of corticosteroids and anti-inflammatory therapy, the prognosis was 
detrimental and survival of IIM was very low.[119, 187]  In mortality studies from the 70ties, 
the outcome of IIM remained poor [91] with a five year survival rate lower than 50%.[4, 92-
95] The more recent studies show mortality ratio in DM/PM patients remain threefold higher 
compared with the general population, with cancer, infection, lung and cardiac complications 
being the most common causes of deaths.[91]  
Later work has confirmed this, but shown large variation in mortality rates, probably due to 
differences in patient selection, classification and loss to follow-up. [91]
     Compared to the Norwegian background population, our cohort of 326 unselected IIM 
patients had decreased survival. Our study finds that the 10 year survival of  55% and 60% in 
DM and PM respectively, are no higher than previously observed in single-centre cohorts, 
[91, 97, 104]. The 10 year survival in sIBM was even lower (42%) in our cohort, but the low 
concurring survival in the matched controls (57%) showed that this was an effect of age. The 
age effect was also apparent in the risk factor analyses where mean age at diagnosis stood out 
as an important determinant of mortality across all the IIM cohorts 
Hazard ratios were increased in all IIM subsets for cancer, highest in the DM, as seen in 
previous studies. [91, 104, 188, 189]. Reduced pulmonary function, expressed by FVC <70% 
and DLCO <60% were associated with increased mortality. These data appear in line with a 
study on 107 PM/DM patients where reduced FVC and DLCO were associated with 
mortality.[12]
Several previous studies have reported decreased survival in PM/DM patients with MAA [91, 
99, 190-193]. Surprisingly, in our cohort MAA did not increase the Hazard ratio in any of the 
IIM subgroups. We speculate that this may be an effect of differential patient selection. Our 
62

PM/DM cases were unselected, while the previous studies were from specialized centres that 
possibly selects for PM/DM patients with more severe disease and higher frequency of MAA-
related organ complications like ILD and PH. Another possibility is that the recent availability 
of more efficient treatment has improved the relative survival of MAA positive patient 
subsets.
The major causes of death in our cohort PM/DM were cancer, infections and respiratory 
failure due to ILD and/or secondary PH, as reported by others.[23, 90, 91, 188] Interestingly, 
in sIBM it appeared that the major cause of death was a potentially preventable complication 
(aspiration secondary to oesophagus dysmotility). In conclusion the mortality of PM/DM 
remains high in Norway and some of the disease-related deaths in sIBM are potentially 
preventable.  
63

5.1.7 How do we follow our IIM patients with increased risk of mortality and clinical 
implications?    
Discussion on standards of care should always be a priority and an aim for international 
collaboration. To date the standards of care differ even amongst specialists. Therefore the aim 
should be to have international agreed consensus of “best practice” which can dramatically 
improve patient`s quality of life and in some cases increase survival. The international best 
practice guidelines should also encompass same diagnostic criteria sets, investigative and 
follow-up practice and same level of care. 
In sIBM patients the aims could be to 
1) Reduce diagnostic delay by awareness, education and standard diagnostic criteria 
utilized by doctors and allied health care personnel. 
2) To investigate the possibility of dysphagia by radiological imaging and awareness. 
And to treat nutritional impairment and refer to Ear Nose Throat (ENT) specialists 
where surgical options are a possibility.
3) A treatment trial consisting of at least a short-term corticosteroids therapy and 
Methotrexate could possibly be standard care, especially in patients with other 
rheumatic inflammatory disorders. 
4) Supportive management, orthotics, adaptive devices and exercise with 
physiotherapists could be sought. 
5) Clinical trials of new potential beneficial treatments and international collaboration. 
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In PM/DM patients: 
1) Focus should also be on awareness and education of health professionals and doctors 
and international collaboration for the usage of same diagnostic criteria and same level 
of care. 
2) Focus initially should be on cancer screening, especially of DM patients. All patients, 
especially MAA positive, could be investigated at debut with; 
 a) HRCT of the lungs to exclude ILD and pulmonary complications 
b) Pulmonary function tests (PFT) 
c) Echocardiography to monitor and exclude the development of Pulmonary 
Hypertension.
d) In addition to the diagnostic investigations; blood samples for muscle enzymes, 
ESR, autoantibodies and MAA. EMG/neurography, radiological studies of the 
oesophagus, MRI of thigh muscles and muscle biopsy. 
The patients at risk could possibly annually be followed by serial HRCT of the lungs, PFTs 
and Echocardiography. 
3) Patients would possibly benefit from receiving tailored treatment according to 
phenotypes, internationally standardized.
4) A focus of treatment and prophylactic antibiotics should be given to severely 
immunosuppressed patients, especially those with organ-damage, to reduce infection-
associated mortality. 
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5) The follow-up during the first years of diagnosis should be most extensive, due to the
         fact that most disease-related deaths occur during the first years of diagnosis. 
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5.2 Future perspectives: 
The aim of this large epidemiological study was to map the prevalence, clinical characteristics 
and cancer and mortality of IIM in South-east Norway. With ambition to ultimately obtain 
better knowledge of the disorders that encompasses IIM and their outcomes. We do, however, 
have concrete plans and wishes for further studies, as there is yet unpublished clinical data 
and important aspects to elaborate. We especially want to further investigate the recent trial 
on novel MAA undertaken on approximately 152 of our patients. (Sanner et.al) The results 
from this study indicate that the new MAA may aid clinical decision making in adult IIM, 
especially in patients negative for anti-synthetase and anti-SRP antibodies. We wish to 
include   the entire IIM cohort, in order to test this hypothesis further. In addition, we also 
plan and aim to undertake further genetic and molecular studies and we hope to extend the 
cohort nationally to include the whole of Norway. We also wish and hope we are able to 
contribute internationally with clinical data to give more grounds for larger research, through 
MYONET and other collaborative efforts. We do believe that this is the way forward to 
increase the level of care of IIM patients in Norway. 
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Appendix I: 
Selected abbreviations 
ANA        anti-nuclear antibody 
ANM      autoimmune necrotizing myopathy 
Anti-HMG-CoA    3-hydroxy-3-methylglutaryl-coenzyme A reductase 
Anti-SSA: Sjøgren`s syndrome A antibody 
Anti-SRP: Anti-Signal Recognition Particle  
ASS Anti-synthetase syndrome 
Aza: Azathioprine 
CI: Confidence Interval 
CK: Creatine Kinase enzyme 
COP Cryptogenic organizing pneumonia 
CTD: Connective tissue disease 
CYC: Cyclophosphamide 
DLCO: Diffusion Capacity of carbon monoxide 
DM Dermatomyositis 
EMG: Electromyography 
ENMC: European Neuro-Muscular Centre 
ESR Erythrocyte Sediment Rate 
FEV1 Forced expired volume in one second 
FVC forced vital capacity 
GC Glucocorticosteroids 
HLA Human leucocyte antigen 
HRCT thorax high resolution computed tomography 
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ICD10 International Classification of Diseases 10th version 
IG Immunoglobulin 
IIM idiopathic inflammatory myopathy 
IMMCP: International Myositis Classification Criteria Project 
ILD Interstitial lung disease 
IPF Idiopathic Pulmonary fibrosis 
MHC major histocompatibility complex 
MAA myositis associated autoantibodies 
MMF Mycophenolate mofetil 
MMT manual muscle test 
MTX Methotrexate 
MRC scale: Medical Research Council scale 
MRI Magnetic resonance imaging 
MSA myositis specific antibodies 
NOSVAR Norwegian Systemic Connective Tissue and Vasculitis Registry 
NSIP Non-specific interstitial pneumonia 
PH Pulmonary hypertension 
PM Polymyositis 
pSS primary Sjøgren Syndrome 
RA rheumatoid arthritis 
REK Regional Committee for Research Ethics 
RTX Rituximab 
SD Standard Deviation 
sIBM: Sporadic inclusion body myositis 
SLE Systemic lupus erythematosus 
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SMR: Standard mortality rate 
SIR: Standard incidence rate 
SNOMED: Systematic Nomenclature of Medicine code system 
UIO University of Oslo 
UIP usual interstitial pneumonia 
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Errata 
Paragraph 1.1.2, page 11; changed from; 
while, the Gottron`s papules are typically described as symmetrical papules over the extensor 
(dorsal) aspects of the metatarsophalangeal (MCP) and interphalangeal (IP) joints, The 
Gottrons sign is the same rash as above when present on the extensor surfaces of other joints 
To: 
while the Gottron`s papules are typically described as erythematous to violaceous papules 
over the extensor surfaces of joints, which are sometimes scaly. This manifestation may occur 
over the finger joints, elbows, knees, malleoli and toes. The Gottrons sign is erythematous to 
violaceous macules over the extensor surfaces of joints, which are not palpable. 
Paragraph 1.1.6, page 16 to18. 
Changed Myositis Associated Autoantibodies (MAA) to Myositis Specific Autoantibodies 
(MSA) throughout this paragraph. 
 
